You are here

Axovant

Sio Gene could be a canary in the coalmine for gene therapy

EP Vantage

Thu, 04/28/22 - 10:42 am

In quick start to new year's M&A, Arvelle Therapeutics hands reins to Angelini as it nears EU approval for cenobamate

Endpoints

Mon, 01/4/21 - 10:41 am

Arvelle Therapeutics

Angelini Pharma

Axovant Changes Name to Sio Gene Therapies, Adding to List of Biopharma Company Rebrands

BioSpace

Tue, 11/10/20 - 07:42 pm

Sio Gene Therapies

Upcoming events – Avadel takes on Jazz and Axovant awaits early results

EP Vantage

Fri, 02/14/20 - 10:35 am

Jazz Pharmaceuticals

Parkinson's Disease

Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival

Endpoints

Tue, 03/19/19 - 10:30 am

Alzheimer's disease

Vivek Ramaswamy

urinary incontinence

Axovant trumpets new clinical data after gene therapy pivot

Fierce Biotech

Mon, 03/11/19 - 10:11 pm

Parkinson's Disease

Axovant axes neuroscience drug, focuses on gene therapies

Pharmaforum

Wed, 12/12/18 - 10:02 am

Axovant dumps nelotanserin in retreat from small molecule R&D

Fierce Biotech

Mon, 12/10/18 - 10:01 am

dementia with Lewy bodies

clinical trials

small molecule drugs

Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline

Endpoints

Mon, 11/26/18 - 10:08 am

Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica

CP Wire

Wed, 06/6/18 - 09:29 am

Oxford BioMedica

Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica

Wed, 06/6/18 - 09:25 am

Oxford BioMedica

The stint that never happened? Biotech vet David Hung wipes Axovant from his work history

Stat

Tue, 04/10/18 - 10:20 pm

David Hung makes a quick, abrupt exit at Axovant after humiliating setbacks

Endpoints

Mon, 02/12/18 - 09:11 am

The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug

Stat

Thu, 09/7/17 - 09:35 am

Alzheimer's disease

Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s

EP Vantage

Sat, 08/26/17 - 07:46 pm

Alzheimer's disease

The sector’s most valuable unpartnered assets – up for grabs or on the shelf?

EP Vantage

Tue, 08/22/17 - 09:55 am

Portola Pharmaceuticals

DBV Technologies

3 Small Biotech Stocks Being Run by Proven Winners

Motley Fool

Mon, 07/17/17 - 11:15 am

Esperion Therapeutics

Aurinia Pharmaceuticals

Richard Glickman

Key FDA Decision And Trial Dates In February

Seeking Alpha

Mon, 01/30/17 - 11:03 pm

Valeant Pharmaceuticals

Lexicon Pharmaceuticals

Amicus Therapeutics

Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies

TheStreet.com

Tue, 11/29/16 - 09:49 am

Alzheimer's disease

Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug

Forbes

Wed, 07/22/15 - 09:43 pm

Alzheimer's disease

Pages